Missed opportunities for osteoporosis management in older patients: A literature review

Primary Health Care Research and Development

Volumn 11, Issue 2, 2010, Pages 155-165

  Manek, Nishma ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

fragility fracture; investigation; osteoporosis; secondary bone prevention

Indexed keywords

EID: 85011519658     PISSN: 14634236     EISSN: 14771128     Source Type: Journal    
DOI: 10.1017/S1463423609990429     Document Type: Article

References (31)

1. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R. 1995: Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in a primary care setting? New England Journal of Medicine 332, 1125–1131.
2. Andrade S.E., Majumdar S.R., Chan K.A., Buist D.S., Go A.S., Goodman M., Smith D.H., Platt R., Gurwitz J.H. 2003: Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Archives of Internal Medicine 163, 2052–2057.
3. Bessette L., Ste-Marie L.G., Jean S., Davison K.S., Beaulieu M., Baranci M., Bessant J., Brown J.P. 2008: The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos International 9, 79–86.
4. Borgström F., Ström O., Coelho J., Johansson H., Oden A., McCloskey E.V., Kanis J. 2009: The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX(R). Osteoporos International [Epub ahead of print].
5. Brown M.A., Bradio N. 2000: Cost effectiveness of bone density measurement. Journal of the British Menopause Society 7, 130–135.
6. Bush G.W. 2002: Nation Bone and Joint Decade Proclamation. Office of the Press Secretary, 22 March 2002.
7. Chami G., Jeys L., Freudmann M., Connor L., Siddiqi M. 2006: Are osteoporotic fractures bein adequately investigated? a questionnaire of GP and orthopaedic surgones. BMC Family Practice 7, 7.
8. Diel I., Bergner I., Grötz K. 2007: Adverse effects of bisphosphonates: current issues. Journal of Supportive Oncology 5, Retrieved 20 September 2009 from http://www.supportiveoncology.net/journal/articles/0510475.pdf. 18240669
9. Dreinhöfer K.E., Féron J.M., Herrera A., Hube R., Johnell O., Lidgren L., Miles K., Panarella L., Simpson H., Wallace W.A. 2004: Orthopaedic surgeons and fragility fractures. A survey by the bone and joint decade and the international osteoporosis foundation. Journal of Bone and Joint Surgery British volume 86, 958–961.
10. Elliot-Gibson V., Bogoch E.R., Jamal S.A., Beaton D.E. 2004: Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis International 15, 767–778.
11. Epstein S., Goodman G.R. 1999: Improved strategies for diagnosis and treatment of osteoporosis. Menopause 6, 242–250. 10486795
12. Ferrari S. 2008: Secondary prevention of osteoporotic fractures: why not apply the evidence? Swiss Medical Weekly 138, 674–683. 18855150
13. Freedman B.A., Potter B.K., Nesti L., Giuliani J., Chadwick H., Kuklo T. 2008: Osteoporosis and vertebral compression fractures-continued missed opportunities. The Spine Journal 8, 756–762.
14. Gehlbach S.H., Avrunin J.S., Puleo E., Spaeth R. 2007: Fracture risk and antiresorptive medication use in older women in the USA. Osteoporosis International 18, 805–810
15. Giangregorio L., Papaioannou A., Cranney A., Zytarukm N., Adachim J.D. 2006: Fragility fractures and the osteoporosis care gap: an international phenomenon. Seminars in Arthritis Rheumatism 35, 293–305.
16. Harrington J.T., Barash H.L., Day S., Lease J. 2005: Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheumatism 53, 198–204.
17. Hooven F., Gehlbach S.H., Pekow P., Bertone E., Evan B. 2005: Follow up treatment for osteoporosis after fracture. Osteoporosis International 16, 296–301.
18. Kamatari M., Koto S., Ozawa N., Urao C., Suzuki Y., Akasaka E., Yanagimoto K., Sakota K. 2007: Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. Journal of Bone Mineral Metabolism 25, 302–309.
19. Khaw K.T. 1999: How many, how old, how soon? British Medical Journal 319, 13500–13502.
20. Marsh D., Simpson H., Wallace A. 2003: The care of fragility fracture patients. London: BOA.
21. McClung B., McClung M. 2001: Pharmacologic therapy for the treatment and prevention of osteoporosis. The Nursing Clinics of North America 36, 433–440. 11532658
22. McClung M.R., Lewiecki E.M., Cohen S.B. 2006: Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine 354, 821–831.
23. NICE Guidelines. 2003: Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. [Online]. Retrieved 12 November 2008 from http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=11621
24. NICE Guidelines. 2008: Osteoporosis: secondary prevention (replaced by TA161). [Online]. Retrieved 12 September 2009 from http://guidance.nice.org.uk/TA87
25. National Osteoporosis Foundation. 1999: Physicians’ Guide to Prevention and Treatment of Osteoporosis. [Online]. Retrieved 26 November 2008 from http://www.nof.org/physguide.htm
26. Nixon M.F., Ibrahim T., Johari Y., Eltayef S., Hariharan T., Taylor G.J. 2007: Managing osteoporosis in patients with fragility fractures: did the British Orthopaedic Association guidelines have any impact? Annals of the Royal College of Surgeons of England 89, 504–509.
27. Papaioannou A., Kennedy C.C., Ioannidis G., Gao Y., Sawka A.M., Goltzman D., Tenenhouse A., Pickard L., Olszynski W.P., Davison K.S., Kaiser S., Josse R.G., Kreiger N., Hanley D.A., Prior J.C., Brown J.P., Anastassiades T., Adachi J.D. 2008: The osteoporosis care gap in men with fragility fractures: the Canadian multicentre osteoporosis study. Osteoporosis International 19, 581–587.
28. Perreault S., Dragomir A., Desgagné A., Blais L., Rossignol M., Blouin J., Moride Y., Ste-Marie L.G., Fernandès J.C. 2005: Trends and determinants of antiresorptive drug use for osteoporosis amongst elderly women. Pharmacoepidemiology Drug Safety 14, 685–695.
29. Prasad N., Sunderamoorthy D., Martin J., Murray J.M. 2006: Secondary prevention of fragility fractures: are we following the guidelines? Closing the audit loop. Annals of the Royal College of Surgeons of England 88, 470–474.
30. Simonelli C., Killeen K., Mehle S., Swanson L. 2002: Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clinic Proceedings 77, 334–338.
31. Suhm N., Lamy O., Lippuner K. 2008: Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Medical Weekly 138, 656 [Early Online Publication]. Retrieved 14 November 2008 from http://74.125.77.132/search?q=cache:07liX4yn57YJ:www.smw.ch/docs/pdf200x/2008/45/smw-12294.PDF+Suhm,+N.,+Lamy,+O.,+Lippuner,+K+(2008).+Management+of+fragility+fractures+in+Switzerland:+results+of+a+nationwide+survey.+Swiss+Medical+Weekly&hl=en&ct=clnk&cd=2 19043812